RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells

Neurobiology of Disease

Volumn 54, Issue , 2013, Pages 264-279

  Pranski, Elaine L ^a   Dalal, Nirjari V ^a   Sanford, Carson Van ^a   Herskowitz, Jeremy H ^a   Gearing, Marla ^a   Lazo, Carlos ^a   Miller, Gary W ^a   Lah, James J ^a   Levey, Allan I ^a   Betarbet, Ranjita S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 Hydroxydopamine; 6 OHDA; AAV; Antioxidants; E3 ligase; Human tissue; Neurodegeneration; NF B; Parkinson's disease

Indexed keywords

AMPHETAMINE; BCL2 RELATED PROTEIN A1; BRAIN DERIVED NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OXIDOPAMINE; RING FINGER PROTEIN; RING FINGER PROTEIN 11; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CELL SURVIVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCEPHALON; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; STRIATONIGRAL DEGENERATION;

ADRENERGIC AGENTS; AGED; AGED, 80 AND OVER; ANIMALS; CARRIER PROTEINS; DOPAMINERGIC NEURONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NERVE DEGENERATION; NF-KAPPA B; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TRANSFECTION;

EID: 84876314819     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.12.018     Document Type: Article

References (106)

1. Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000, 35:151-159.
2. Anderson L.R., et al. PARK10 candidate RNF11 is expressed by vulnerable neurons and localizes to Lewy bodies in Parkinson disease brain. J. Neuropathol. Exp. Neurol. 2007, 66:955-964.
3. Aoki E., et al. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp. Mol. Pathol. 2009, 86:57-64.
4. 2+ accumulation. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9328-9332.
5. Bartus R.T., et al. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol. Dis. 2011, 44:38-52.
6. Betarbet R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
7. Betarbet R., et al. Animal models of Parkinson's disease. Bioessays 2002, 24:308-318.
8. Bezard E., et al. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov. Disord. 2012, 10.1002/mds.25108.
9. Blum D., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
10. Boersma M.C.H., et al. A requirement for nuclear factor-κB in developmental and plasticity-associated synaptogenesis. J. Neurosci. 2011, 31:5414-5425.
11. Braak H., et al. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J. Neurol. Sci. 2006, 248:255-258.
12. Bruce A.J., et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 1996, 2:788-794.
13. Cao S., et al. Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol. Neurodegener. 2010, 5:42.
14. Chen H., et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 2005, 58:963-967.
15. Cheng B., et al. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994, 12:139-153.
16. Coelho M., Ferreira J.J. Late-stage Parkinson disease. Nat. Rev. Neurol. 2012, 8:435-442.
17. Costanzo A., et al. NF-κB, IκB Kinase and Interacting Signal Networks in Squamous Cell Carcinomas Signaling Pathways in Squamous Cancer 2011, 201-222. Springer, New York. A.B. Glick, C.V. Waes (Eds.).
18. Cova L., et al. Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson's disease. Apoptosis 2012, 17:289-304.
19. Crossman A.R. Neural mechanisms in disorders of movement. Comp. Biochem. Physiol. A Comp. Physiol. 1989, 93:141-149.
20. Davis A.A., et al. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J. Neurosci. 2010, 30:4190-4196.
21. Decressac M., et al. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp. Neurol. 2012, 235:306-315.
22. Elkon H., et al. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. J. Mol. Neurosci. 2004, 24:387-400.
23. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 2003, 991:1-14.
24. Ferger B., et al. Genetic ablation of tumor necrosis factor-alpha (TNF-α) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 2004, 89:822-833.
25. Fernyhough P., et al. Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. J. Neurosci. 2005, 25:1682-1690.
26. Flood P.M., et al. Transcriptional factor NF-kappaB as a target for therapy in Parkinson's disease. Parkinsons Dis. 2011, 2011:216298.
27. Frank-Cannon T., et al. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol. Neurodegener. 2009, 4:47.
28. Galardi S., et al. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 2011, 39:3892-3902.
29. Gantier M.P., et al. A miR-19 regulon that controls NF-κB signaling. Nucleic Acids Res. 2012, 40:8048-8058.
30. Gasmi M., et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol. Dis. 2007, 27:67-76.
31. Gerhard A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412.
32. German D.C., Manaye K.F. Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J. Comp. Neurol. 1993, 331:297-309.
33. Ghosh A., et al. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. 2007, 104:18754-18759.
34. Glass C.K., et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
35. González-Scarano F., Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 1999, 22:219-240.
36. Gordon J.W., et al. Multiple facets of NF-κB in the heart. Circ. Res. 2011, 108:1122-1132.
37. Graham D.G., et al. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 1978, 14:644-653.
38. Grau C.M., Greene L.A. Use of PC12 Cells and Rat Superior Cervical Ganglion Sympathetic Neurons as Models for Neuroprotective Assays Relevant to Parkinson's Disease Neurotrophic Factors 2012, 201-211. Humana Press. S.D. Skaper (Ed.).
39. Hald A., Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp. Neurol. 2005, 193:279-290.
40. Hamza T.H., et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 2010, 42:781-785.
41. Hirsch E.C. Mechanism and consequences of nerve cell death in Parkinson's disease. J. Neural. Transm. 1999, Supplement 56:127-137.
42. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
43. Hirsch E.C., et al. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11:S9-S15.
44. Holtz W.A., et al. Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J. Neurochem. 2006, 99:54-69.
45. Hunot S., et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7531-7536.
46. Hutson C.B., et al. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J. Neurotrauma 2011, 28:1783-1801.
47. Imielski Y., et al. Regrowing the adult brain: NF-κB controls functional circuit formation and tissue homeostasis in the dentate gyrus. PLoS One 2012, 7:e30838.
48. Jellinger K.A. Cell death mechanisms in neurodegeneration. J. Cell Mol. Med. 2001, 5:1-17.
49. Kaltschmidt B., et al. Inhibition of NF-κB potentiates amyloid β-mediated neuronal apoptosis. Proc. Natl. Acad. Sci. 1999, 96:9409-9414.
50. Kaltschmidt B., et al. Signaling via NF-κB in the nervous system. Biochim. Biophys. Acta 2005, 1745:287-299.
51. Kirik D., et al. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 1998, 152:259-277.
52. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
53. Krikos A., et al. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J. Biol. Chem. 1992, 267:17971-17976.
54. Lee E.G., et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354.
55. Lee J.-K., et al. Neuroinflammation in Parkinson's Disease. J. Neuroimmune Pharmacol. 2009, 4:419-429.
56. Lee J.-K., et al. Regulator of G-protein signaling-10 negatively regulates NF-κB in microglia and neuroprotects dopaminergic neurons in hemiparkinsonian rats. J. Neurosci. 2011, 31:11879-11888.
57. Li Z., et al. Forkhead transcription factor FOXO3a activates NF-kB through B-cell lymphoma/leukemia (BCL10) and promotes tumor cell survival in serum-deprivation. J. Biol. Chem. 2012, 287:17737-17745.
58. Liang Z.Q., et al. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res. 2007, 1145:190-203.
59. Liu S., Chen Z.J. Expanding role of ubiquitination in NF-kappaB signaling. Cell Res. 2011, 21:6-21.
60. Lotharius J., et al. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 1999, 19:1284-1293.
61. Lu D.-Y., et al. Resistin protects against 6-hydroxydopamine-induced cell death in dopaminergic-like MES23.5 cells. J. Cell. Physiol. 2012, 228:563-571.
62. Maggirwar S.B., et al. Nerve growth factor-dependent activation of NF-kappaB contributes to survival of sympathetic neurons. J. Neurosci. 1998, 18:10356-10365.
63. Mangano E.N., et al. Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease. Neurobiol. Dis. 2011, 43:99-112.
64. Marchetti L., et al. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-d-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem. 2004, 279:32869-32881.
65. Mattson M.P., Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 2001, 107:247-254.
66. Mattson M.P., Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006, 13:852-860.
67. Mattson M.P., et al. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J. Neurosci. Res. 1997, 49:681-697.
68. Mazzon C., et al. Agrin is required for survival and function of monocytic cells. Blood 2012, 119:5502-5511.
69. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 2008, 5:45.
70. McCoy M.K., et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 2006, 26:9365-9375.
71. Minghetti L., et al. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res. Rev. 2005, 48:251-256.
72. Mirra S.S., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Neurology 1991, 41:479.
73. Mogi M., et al. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci. Lett. 2007, 414:94-97.
74. Mulcahy P., et al. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-alpha-synuclein and the pesticide, rotenone. Neuroscience 2012, 203:170-179.
75. Nagahara A.H., Tuszynski M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 2011, 10:209-219.
76. Noureddine M.A., et al. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov. Disord. 2005, 20:1299-1309.
77. O'Neill L.A., Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20:252-258.
78. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
79. Panet H., et al. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J. Neurochem. 2001, 77:391-398.
80. Pierce J.W., et al. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 1997, 272:21096-21103.
81. Pranski E.L., et al. Neuronal RING finger protein 11 (RNF11) regulates canonical NF-kappaB signaling. J. Neuroinflammation 2012, 9:67.
82. Pranski E.L., et al. Comparative distribution of protein components of the A20 ubiquitin-editing complex in normal human brain. Neurosci. Lett. 2012, 520:104-109.
83. Rieker C., et al. Ablation of serum response factor in dopaminergic neurons exacerbates susceptibility towards MPTP-induced oxidative stress. Eur. J. Neurosci. 2012, 35:735-741.
84. Roca V., et al. The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation. Parkinson's Dis. 2011, 2011:931572.
85. Ruland J. Return to homeostasis: downregulation of NF-[kappa]B responses. Nat. Immunol. 2011, 12:709-714.
86. Saijo K., et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
87. Shembade N., et al. Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signaling. EMBO J. 2007, 26:3910-3922.
88. Shembade N., et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat. Immunol. 2008, 9:254-262.
89. Shembade N., et al. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J. 2009, 28:513-522.
90. Stahl K., et al. Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease. Brain Res. 2011, 1378:105-118.
91. Sullivan P.G., et al. Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J. Neurosci. 1999, 19:6248-6256.
92. Taglialatela G., et al. Inhibition of nuclear factor kappa B (NFkappaB) activity induces nerve growth factor-resistant apoptosis in PC12 cells. J. Neurosci. Res. 1997, 47:155-162.
93. Tamatani M., et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J. Biol. Chem. 1999, 274:8531-8538.
94. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 2010, 37:510-518.
95. Tarabin V., Schwaninger M. The role of NF-kappaB in 6-hydroxydopamine- and TNFalpha-induced apoptosis of PC12 cells. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369:563-569.
96. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 2000, 166:29-43.
97. Tatton W.G., Chalmers-Redman R.M. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy?. Ann. Neurol. 1998, 44:S134-S141.
98. Ton T.G., et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov. Disord. 2006, 21:964-969.
99. Tran T.A., et al. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J. Neuroinflammation 2008, 5:14.
100. Verstrepen L., et al. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem. Pharmacol. 2010, 80:2009-2020.
101. Volpicelli L.A., et al. Rab5-dependent trafficking of the m4 muscarinic acetylcholine receptor to the plasma membrane, early endosomes, and multivesicular bodies. J. Biol. Chem. 2001, 276:47590-47598.
102. Wang X.-J., et al. CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease. J. Neuroimmune Pharmacol. 2007, 2:259-264.
103. Wilms H., et al. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr. Pharm. Des. 2007, 13:1925-1928.
104. Yin Y., et al. Modulation of neuronal survival factor MEF2 by kinases in Parkinson's disease. Front. Physiol. 2012, 3.
105. Zhang S., et al. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J. Neuroinflammation 2011, 8:154.
106. Zhu T.G., et al. Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci. Lett. 2012, 506:175-179.